covid
Buscar en
Endocrinología y Nutrición
Toda la web
Inicio Endocrinología y Nutrición Concepto, etiología y epidemiología del hiperparatiroidismo primario
Journal Information
Vol. 56. Issue S1.
Puesta al día en hiperparatiroidismo primario
Pages 2-7 (April 2009)
Share
Share
Download PDF
More article options
Vol. 56. Issue S1.
Puesta al día en hiperparatiroidismo primario
Pages 2-7 (April 2009)
Full text access
Concepto, etiología y epidemiología del hiperparatiroidismo primario
Concept, etiology and epidemiology of primary hyperparathyroidism
Visits
21487
Guillermo Martínez Díaz-Guerra
Corresponding author
gmdiazguerra@gmail.com

Correspondencia: Dr. G. Martínez Díaz-Guerra. Servicio de Endocrinología y Nutrición. Residencia General. Planta baja. Hospital Universitario 12 de Octubre. Avda. de Córdoba, s/n. 28041 Madrid. España.
, Federico Hawkins Carranza
Servicio de Endocrinología y Nutrición. Hospital Universitario 12 de Octubre. Madrid. España
This item has received
Article information

El hiperparatiroidismo primario (HP) es uno de los trastornos endocrinológicos más frecuentes. En el HP se produce una regulación anormal de la secreción de parathormona (PTH) por el calcio, que se traduce en una secreción de PTH inapropiadamente alta para el grado de calcemia. La mayoría de pacientes con HP presentan valores aumentados de PTH sérica, con aumento de las concentraciones de calcio sérico, especialmente el calcio iónico. La incidencia aumenta con la edad, y la edad media al diagnóstico es de 55 años. Afecta predominantemente a las mujeres, con una proporción aproximada de 3:1, respecto a los varones. El 80-85% de los casos están producidos por un adenoma paratiroideo de células principales. Los factores implicados en la génesis del HP son en gran parte desconocidos. En una minoría se encuentran mutaciones genéticas que afectan a oncogenes (ciclina D1, RET) o genes supresores tumorales (MEN1, HRPT2). Tienen especial relevancia en las formas de HP familiares, como el síndrome de neoplasia endocrina múltiple (MEN1, MEN2A). No se han encontrado mutaciones que afecten al sensor-receptor de calcio (CaSR) o al gen del receptor de vitamina D (VDR).En los adenomas e hiperplasias paratiroideas puede existir una señalización anormal de la vía Wnt, con mutaciones del gen del correceptor LRP5 y acumulación de β-catenina. La expresión de la proteína Klotho, que interviene en la regulación del calcio sérico, está disminuida. Con frecuencia, pueden coexistir valores bajos de 25(OH) vitamina D, aunque se desconoce si la deficiencia de vitamina D tiene un papel patogénico en el HP.

Palabras clave:
Adenoma paratiroideo
Ciclina D1
RET
HRPT2
β-catenina
Klotho

Primary hyperparathyroidism (PHPT) is one of the most frequent endocrinological disorders. In PHPT, there is abnormal regulation of parathyroid hormone (PTH) by calcium, which translates into inappropriately high PTH secretion for the level of calcemia. Most patients with PHPT have increased serum PTH levels, with increases in serum calcium, especially ionic calcium. The incidence of PHPT rises with age, the mean age at diagnosis being 55 years. This disorder affects mainly women with a female-to-male ratio of approximately 3:1.

Most (80-85%) of cases are produced by chief cell parathyroid adenomas. The factors involved in the genesis of PHPT are largely unknown. Gene mutations affecting oncogenes (cyclin D1, RET) or tumor suppressor genes (MEN1, HRPT2) are found in a minority of cases. These mutations are especially important in familial forms of PHPT, such as multiple endocrine neoplasia syndrome (MEN1, MEN2A). No mutations affecting the calcium-sensing receptor (CaSR) or vitamin D receptor (VDR) gene have been found.

In parathyroid adenomas and hyperplasias, there may be abnormal Wnt signalling, with mutations of the coreceptor LRP5 gene and β-catenin accumulation.

Expression of the Klotho protein, which intervenes in serum calcium regulation, is reduced. Low levels of 25(OH) vitamin D frequently coexist, although whether vitamin D deficiency plays a pathogenic role in PHPT is unknown.

Key words:
Parathyroid adenoma
D1 cyclin
RET
HRPT2
β-catenin
Klotho
Full text is only aviable in PDF
Bibliografía
[1.]
E.M. Brown.
Extracellular Ca2+ sensing, regulation of parathyroid cell function, and role of Ca2+ and other ions as extracellular (first) messengers.
Physiol Rev, 71 (1991), pp. 371-411
[2.]
S.J. Marx.
Medical Progress: hyperparathyroid and hypoparathyroid disorders.
N Engl J Med, 343 (2000), pp. 1863-1875
[3.]
E.M. Brown.
Four-parameter model of the sigmoidal relationship between parathyroid hormone release and extracellular calcium concentration in normal and abnormal parathyroid tissue.
J Clin Endocrinol Metab, 56 (1983), pp. 572-581
[4.]
O. Kifor, F.D. Moore Jr, P. Wang, M. Goldstein, P. Vassilev, I. Kifor, et al.
Reduced immunostaining for the extracellular Ca2+-sensing receptor in primary and uremic secondary hyperparathyroidism.
J Clin Endocrinol Metab, 81 (1996), pp. 1598-1606
[5.]
F. Cetani, A. Picone, P. Cerrai, E. Vignali, S. Borsari, E. Pardi, et al.
Parathyroid expression of calcium-sensing receptor protein and in vivo parathyroid hormone-Ca(2+) set-point in patients with primary hyperparathyroidism.
J Clin Endocrinol Metab, 85 (2000), pp. 4789-4794
[6.]
F. Farnebo, U. Enberg, L. Grimelius, M. Backdahl, M. Schalling, C. Larsson, et al.
Tumor-specific decreased expression of calcium sensing receptor messenger ribonucleic acid in sporadic primary hyperparathyroidism.
J Clin Endocrinol Metab, 82 (1997), pp. 3481-3486
[7.]
R.A. Wermers, S. Khosla, E.J. Atkinson, S.J. Hodgson, W.M. O’Fallon, L.J. Melton III.
The rise and fall of primary hyperparathyroidism: a population-based study in Rochester, Minnesota, 1965-1992.
Ann Intern Med, 126 (1997), pp. 433-440
[8.]
R.A. Wermers, S. Khosla, E.J. Atkinson, S.J. Achenbach, A.L. Oberg, C.S. Grant, et al.
Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993-2001: an update on the changing epidemiology of the disease.
J Bone Miner Res, 21 (2006), pp. 171-177
[9.]
M. Palmer, G. Jacobsson, G. Akerstrom, S. Ljunghall.
Prevalence of hypercalcemia in a health survey: a 14-year follow-up study of serum calcium values.
Eur J Clin Invest, 18 (1988), pp. 39-46
[10.]
E. Lundgren, P. Ridefelt, G. Akerstrom, S. Ljunghall, J. Rastad.
Parathyroid tissue in normocalcemic and hypercalcemic primary hyperparathyroidism recruited by health screening.
World J Surg, 20 (1996), pp. 727-734
[11.]
E. Lundgren, J. Rastad, E. Thurfjell, G. Akerstrom, S. Ljunghall.
Population-based screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women.
Surgery, 126 (1997), pp. 433-440
[12.]
B.S. Miller, J. Dimick, R. Wainess, R.E. Burney.
Age- and sex-related incidence of surgically treated primary hyperparathyroidism.
World J Surg, 32 (2008), pp. 795-799
[13.]
R.A. DeLellis, P. Mazzaglia, S. Mangray.
Primary hyperparathyroidism. A current perspective.
Arch Pathol Lab Med, 132 (2008), pp. 1251-1262
[14.]
C.M. Beard, H. Heath III, W. O’Fallon, J.A. Anderson, J.D. Earle, L.J. Melton III.
Therapeutic radiation and hyperparathyroidism: a case control study in Rochester, Minn.
Arch Intern Med, 149 (1989), pp. 1887-1890
[15.]
A.B. Schneider, T.V. Gierlowski, E. Shore-Freedman, M. Stovall, E. Ron, J. Lubin.
Dose-response relationships for radiation-indu-ced hyperparathyroidism.
J Clin Endocrinol Metab, 80 (1995), pp. 254-257
[16.]
S. Fujiwara, R. Sposto, H. Ezaki, S. Akiba, K. Neriishi, K. Kodama, et al.
Hyperparathyroidism among atomic bomb survivors in Hiroshima.
Radiat Res, 130 (1992), pp. 372-378
[17.]
S.M. Colaco, M. Si, E. Reiff, O.H. Clark.
Hyperparathyroidism alter radioactive iodine therapy.
[18.]
N. Palanisamy, Y. Imanishi, P.H. Rao, H. Tahara, R.S. Chaganti, A. Arnold.
Novel chromosomal abnormalities identified by comparative genomic hybridization in parathyroid adenomas.
J Clin Endocrinol Metab, 83 (1998), pp. 1766-1770
[19.]
M. Fu, C. Wang, Z. Li, T. Sakamaki, R.G. Pestell.
Mini reviews: cyclin D1: normal and abnormal functions.
Endocrinology, 145 (2004),
[20.]
A. Arnold, T.M. Shattuck, S.M. Mallya, L.J. Krebs, J. Costa, J. Gallagher, et al.
Molecular pathogenesis of primary hyperparathyroidism.
J Bone Miner Res, 17 (2002), pp. N30-N36
[21.]
Y. Imanishi, Y. Hosokawa, K. Yoshimoto, E. Schipani, S. Mallya, A. Papanikolaou, et al.
Primary hyperparathyroidism caused by parathyroid-targeted overexpression of cyclin D1 in transgenic mice.
J Clin Invest, 107 (2001), pp. 1093-1102
[22.]
C. Heppner, M.B. Kester, S.K. Agarwal, L.V. Debelenko, M.R. Emmert-Buck, S.C. Guru, et al.
Somatic mutation of the MEN1 gene in parathyroid tumours.
Nat Genet, 16 (1997), pp. 375-378
[23.]
R.V. Thakker.
Diseases associated with the extracellular calcium-sensing receptor.
Cell Calcium, 35 (2004), pp. 275-282
[24.]
T.M. Shattuck, S. Valimaki, T. Obara, R.D. Gaz, O.H. Clark, D. Shoback, et al.
Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma.
N Engl J Med, 349 (2003), pp. 1722-1729
[25.]
C. Marcocci, F. Cetani, M.R. Rubin, S.J. Silverberg, A. Pinchera, J.P. Bilezikian.
Review: Parathyroid carcinoma.
J Bone Miner Res, 23 (2008), pp. 1869-1880
[26.]
W.F. Simonds, O. James-Newton, A.K. Agarwal, B. Yang, M.C. Skarulis, G. Hendy, et al.
Familial isolated hyperparathyroidism:clinical and genetic characterizations of 36 kindreds.
Medicine, 81 (2002), pp. 1-26
[27.]
P. Börklund, G. Akerström, G. Westin.
Accumulation of nonphosphorylated beta-catenin and c-myc in primary and uremic secondary hyperparathyroid tumors.
J Clin Endocrinol Metab, 92 (2007), pp. 338-344
[28.]
P. Börklund, G. Akerström, G. Westin.
An LRP5 receptor with internal deletion in hyperparathyroid tumors with implications for deregulated Wnt/β-catenin signalling.
Plos Medicine, 4 (2007), pp. 1829-1841
[29.]
A. Imura, Y. Tsuji, M. Murata, R. Maeda, K. Kubota, A. Iwano, et al.
Alpha-Klotho as a regulator of calcium homeostasis.
Science, 316 (2007), pp. 1615-1618
[30.]
P. Börklund, T. Krajisnik, G. Akerström, G. Westin, T. Larsson.
Type I membrane klotho expression is decreased and inversely correlated to serum calcium in primary hyperparathyroidism.
J Clin Endocrinol Metab, 93 (2008), pp. 4152-4157
[31.]
E.H. Samander, A. Arnold.
Mutational analysis of the vitamin D receptor does not support its candidacy as a tumor suppressor gene in parathyroid adenomas.
J Clin Endocrinol Metab, 91 (2006), pp. 5019-5021
[32.]
S.J. Silverberg.
Vitamin D deficiency and primary hyper-parathyroidism.
J Bone Miner Res, 22 (2007), pp. V100-V104
[33.]
J.P. Bilezikian, X. Meng, Y. Shi, S.J. Silverberg.
Primary hyperparathyroidism in women: New York and Beijing- A tale of two Cities.
Int J Fertil Womens Med, 45 (2000), pp. 158-165
[34.]
D.S. Rao, M. Honasoge, G.W. Divine, E.R. Phillips, M.W. Lee, M.R. Ansari, et al.
Effect of vitamin D nutrition on parathyroid adenoma weight: pathogenetic and clinical implications.
J Clin Endocrinol Metab, 85 (2000), pp. 1054-1058
[35.]
B. Moosgaard, P. Vestergaard, L. Heickendorff, F. Melsen, P. Christiansen, L. Mosekilde.
Vitamin D status, seasonal variations, parathyroid adenoma weight and bone mineral density in primary hyperparathyroidism.
Clin Endocrinol (Oxf), 63 (2005), pp. 506-513
[36.]
V. Carnevale, G. Manfredi, E. Romagnoli, S. DeGeronimo, F. Paglia, J. Pepe, et al.
Vitamin D status in female patients with primary hyperparathyroidism: Does it play a role in skeletal damage?.
Clin Endocrinol (Oxf), 60 (2004), pp. 81-86
[37.]
R.A. Wermers, A.E. Kearns, G.D. Jenkins, L.J. Melton 3rd.
Incidence and clinical spectrum of thiazide-associated hypercalcemia.
[38.]
S.T. Haden, A.L. Stoll, S. McCormick, J. Scott, G. el-H. Fuleihan.
Alterations in parathyroid dynamics in lithium-treated subjects.
J Clin Endocrinol Metab, 82 (1997), pp. 2844-2848
Copyright © 2009. Sociedad Española de Endocrinología y Nutrición
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos